Position: Chief Development Officer
Dr. Shepard began his career at
Genentech and has supported drug development programs from lead generation
though pivotal development at Merck, Astellas, Celgene, and Boehringer
Ingelheim in the areas of oncology and metabolism. For four years, he was at
Structured BioEquity (SBE) where he in-licensed, structured deals, and built
development programs around Phase 2 drug candidates.
Christopher holds a PhD (Honors)
in Molecular Pathology from the University of Pittsburgh School of Medicine and
an MBA from the Carnegie Mellon Tepper School of Business.